Stockwinners Market Radar for November 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:58 EST Cathie Wood's ARK Investment bought 1.14M shares of Robinhood today

20:39 EST ShoulderUp Technology Acquisition announces letter of intent for combination - ShoulderUp Technology Acquisition Corp. announces letter of intent for a business combination with Airspace Experience Technologies, Inc. ShoulderUp Technology Acquisition announced that that its special meeting of stockholderswill be postponed from its scheduled time of 10:00 a.m. Eastern Time on November 15, 2023 to 4:30 p.m. Eastern Time on November 15, 2023.

19:14 EST B2Gold says on track to meet annual gold output target - The company states: "Based on a strong operational and financial first nine months of 2023, B2Gold is on track to meet its annual total gold production forecast of between 1,000,000 and 1,080,000 ounces (including 60,000 to 70,000 attributable ounces from Calibre) with total consolidated cash operating costs for the year (including estimated attributable results from Calibre) now forecast to be slightly below the original guidance range of between $670 and $730 per ounce and total consolidated all-in sustaining costs (including estimated attributable results for Calibre) are forecast to be at the low end of the original guidance range of between $1,195 and 1,255 per ounce."

19:03 EST MAIA Biotechnology gets Orphan Drug Designation in treatment of malignant glioma - MAIA Biotechnology' treatment of malignant glioma was granted FDA orphan designation, according to a post to the agency's website. Reference Link

18:30 EST Keurig Dr Pepper COO buys $3.12M in common stock as part of option expiry - In a regulatory filing, Keurig Dr Pepper disclosed that its COO Timothy Cofer bought 100K shares of common stock on November 6th as part of option expiry.

18:28 EST ALSP Orchid Acquisition I to redeem public shares - ALSP Orchid Acquisition Corporation I announced that it will redeem all of its outstanding Class A ordinary shares effective as of the close of business on November 14, 2023 or as soon as possible thereafter because the company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association. The per-share redemption price for the Public Shares will be approximately $10.86.

18:20 EST GeoPark announces renewal of share repurchase program - GeoPark concluded its 2023 share repurchase program on November 8, 2023, with 2,223,588 shares acquired, and a total amount invested of $23,611,225 including transaction costs The Board of Directors has approved the renewal, until December 31, 2024, of the repurchase program for up to 10% of its outstanding shares or approximately 5,611,797 shares.

18:00 EST Atara Biotherapeutics trading resumes

17:56 EST Takeda gets FDA approval of Fruzaqla for previously treated colorectal cancer - Takeda announced that the FDA has approved Fruzaqla, an oral targeted therapy for adults with metastatic colorectal cancer, mCRC, who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. Fruzaqla is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.1,2 This approval was received under Priority Review more than 20 days ahead of the scheduled PDUFA date of November 30.

17:52 EST Acutus Medical announces financial impact of corporate restructuring - Going forward, the company's exclusive sources of revenue will come from the sale of left-heart access products at transfer prices specified in Acutus' existing distribution agreement with Medtronic and any fee-bearing transition services, with the company's operating expenses and working capital utilized to support manufacturing, quality, and supply chain related activities as well as general and administrative functions. Under the asset purchase agreement dated April 26, 2022, between Acutus and Medtronic, Acutus is eligible to receive net-sales earnouts under the following terms: 100% of total net end-user sales in year 1; 75% of total net end-user sales in year 2; and 50% of total net end-user sales in years 3 and 4. The annual measurement period for net sales earnouts began on January 30, 2023, and any such earnout payments would begin in April 2024 and continue annually each year thereafter until 2027. As of September 30, the company had $45.5M in cash, cash equivalents, marketable securities, and restricted cash. Once restructuring actions are completed, the Company expects that cash on hand, distribution revenue from left-heart access products to Medtronic, and future earn-outs will be sufficient to service the Company's outstanding debt and fund the remaining business.

17:47 EST Agrify receives extended stay of suspension from Nasdaq - Agrify announced that it received a letter from the hearings panel of Nasdaq notifying Agrify that the stay of suspension for Agrify's common stock will be extended until a hearing before the panel and issuance of a final panel decision.

17:44 EST Atara Biotherapeutics' ATA188 did not meet primary endpoint in sclerosis trial - Atara Biotherapeutics announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis, or PMS. The study did not meet the primary endpoint of confirmed disability improvement compared to placebo. In addition, fluid and imaging biomarkers did not provide further supportive evidence. Preliminary safety data showed there were no new safety signals in the EMBOLD study, reinforcing the favorable safety profile observed with ATA188 to date. Atara is actively reviewing the totality of the data, including a 6% disability improvement in the treatment arm compared to 33% disability improvement observed in the Phase 1 study, to determine the next steps for the program. Going forward, the company plans to significantly reduce its expenses on ATA188 and further focus resources on advancing its differentiated allogeneic CAR-T pipeline, in addition to executing the expanded tab-cel partnership with Pierre Fabre through the Biologics License Application transfer. These future actions are expected to meaningfully extend its cash runway beyond Q3 2025.

17:34 EST Vinci Partners sees R$150B AUM target by year-end 2028 - Vinci Partners posted Fee Related Earnings of R$51.3 M in the 3Q'23, or R$0.95 per common share. Adjusted Distributable Earnings for the quarter reached R$51.8M , or R$0.96 per common share. Alessandro Horta, Chief Executive Officer stated, "We achieved our highest level of management fee revenues since our IPO this quarter, translating into R$0.95 of FRE per share. The fundraising in Private Markets is advancing well and continues to push growth, raising R$1.3 billion across Private Equity, Infrastructure and Real Estate strategies in the third quarter. Furthermore, we recently announced a strategic partnership with Ares, one of the leading alternative asset managers globally, which holds the potential to significantly bolster our fundraising and M&A efforts going forward. We are very optimistic about the future of our business and on course to achieve our R$150 billion AUM target by year-end 2028."

17:25 EST Atara Biotherapeutics trading halted, news pending

17:20 EST ACI Worldwide to replace NextGen Healthcare in S&P 600 at open on 11/13 - Thoma Bravo is acquiring NextGen Healthcare (NXGN) in a deal expected to be completed soon, pending final closing conditions.

17:18 EST Core & Main to replace ACI Worldwide in S&P 400 at open on 11/13

17:07 EST MMTEC regains compliance with Nasdaq minimum bid price deficiency - MMTEC announced that the Company received a notification letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with the Nasdaq's minimum bid price requirement and that the matter is closed. As previously disclosed, MMTec, Inc., received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC on June 27, 2023, indicating that the company was not in compliance with Nasdaq Rule 5550(a)(2), as the closing bid price for the company's common stock had been below $1.00 per share for the preceding 30 consecutive business days. In accordance with the Nasdaq Listing Rules, the company was provided a compliance period of 180 calendar days, or until December 26, 2023, to regain compliance with the Bid Price Rule.

17:03 EST Annovis Bio reports Q3 net loss of $14.7M vs. $6.4M last year - CEO Maria LMaccecchini said, "It is tremendously rewarding and important that our drug is safe, well-tolerated, and easily administered as a once-a-day pill. The only two FDA-approved drugs for Alzheimer's Disease require I.V. infusions and repeated brain imaging, and have well-documented, serious side effects that manifest as brain swelling or brain bleeding. As buntanetap continues to show significant progress through clinical trials, we remain on course and anticipate having topline data with good news to share on our PD study around the end of January 2024, and on our AD study in Q1 of 2024. The positive momentum we're building with this drug is reflected in the more than 800% annual growth rate of our company over the last two years. The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward. There's growing interest and excitement in the scientific and investment communities about our drug's very real potential to not just alleviate devastating neurodegenerative disease symptoms but ultimately change the course of the diseases themselves".

17:00 EST Eli Lilly extends tender offer to acquire Point Biopharma for $12.50 per share - Eli Lilly (LLY) is extending the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Point Biopharma (PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer has been extended until 5:00 p.m., Eastern time, on Nov. 16, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy outstanding closing conditions. The proposed acquisition is expected to close near the end of 2023, subject to customary closing conditions, including the tender of at least a majority of the outstanding Shares as of the expiration of the tender offer.

16:54 EST Lyft reports Q3 gross bookings at $3.55B, up 15% from last year - Reports Q3: "Rides of 187 million: Rides grew 20% year-over-year, reflecting strong growth in rideshare rides (+22% year-over-year) as well as bike and scooter rides. Active Riders of 22.4 million: Active Riders grew 10% year-over-year."

16:41 EST Kodiak Gas Services sees 2023 adjusted EBITDA $430K-$440K

16:39 EST Datadog expands partnership with Google Cloud - Datadog (DDOG) announced an expanded strategic partnership with Google Cloud (GOOG, GOOGL), which enables Google Cloud customers to proactively observe and secure their cloud-native and hybrid applications within Datadog's unified platform. As part of the expanded partnership and integrations, Datadog is one of the first AI/ML observability solution partners for Vertex AI, allowing AI ops teams and developers to monitor, analyze and optimize the performance of their machine learning models in production.

16:39 EST Atmos Energy raises annual dividend 8.8% to $3.22 per share - The company's Board of Directors has declared a quarterly dividend of $0.805 per common share. The indicated annual dividend for fiscal 2024 is $3.22, which represents an 8.8% increase over fiscal 2023.

16:38 EST Fox Corp. names Adam Ciongoli as Chief Legal and Policy Officer - Lachlan Murdoch, Executive Chair and CEO of Fox Corporation (FOX, FOXA), announced that Adam Ciongoli has been appointed Chief Legal and Policy Officer for Fox Corporation beginning December 1. Ciongoli, who currently serves as Executive Vice President, General Counsel and Chief Sustainability, Corporate Responsibility and Governance Officer for Campbell Soup Company, will report to Murdoch. In this role, Ciongoli will lead all legal, compliance, and regulatory matters as well as oversee government affairs. Ciongoli brings nearly 30 years of legal experience in both the public and private sectors to his new role at FOX. Most recently at Campbell (CPB), he led the Legal department, Corporate Secretary function, Government Relations team, and Sustainability, Corporate Responsibility and Governance functions and was a member of the Operating Committee.

16:37 EST Cohen & Steers reports preliminary AUM $72.2B as of October 31 - A decrease of $3B from assets under management at September 30, 2023. The decrease was due to market depreciation of $2.1B, net outflows of $732M and distributions of $154M.

16:36 EST Disney up 4% to $87.65 after Q4 report - Shares of Disney are up $3.15, or 4%, to $87.65 in after-hours trading.

16:30 EST Boise Cascade moves distribution location to Modesto, California - Boise Cascade's Building Materials Distribution division announced that it has completed the purchase of a 20-acre property in Modesto, CA. The Company's current operations in Lathrop, CA, will relocate to this new facility, which includes office space and 190,000 sq. ft. enclosed warehouse served by rail. "We are very excited to join the Modesto community," said Bill Carr, Branch Manager. "This move will better enable us to serve our entire market today as well as put us in a fantastic position for the future."

16:29 EST Genpact CEO Tiger Tyagarajan to retire, BK Kalra to assume CEO role - Genpact announced a leadership succession plan. "Tiger" Tyagarajan, President and CEO, has informed the Board of Directors of his intention to retire from the company, effective February 9, 2024. The company's Board has appointed Balkrishan "BK" Kalra, Genpact's Global Business Leader, Financial Services and Consumer & Healthcare, as Genpact's next CEO. Kalra will join the company's Board on February 9, 2024, and Tyagarajan will continue as a member of the Board of Directors.

16:21 EST MGM Resorts board authorizes $2B share repurchase plan - In addition, on November 8, 2023, the Company announced that its Board of Directors had authorized a new $2 billion share repurchase plan, which is in addition to the Company's existing February 2023 repurchase plan.

16:21 EST B&G Foods sells Green Giant product line - B&G Foods "announced today that it has sold its Green Giant U.S. shelf-stable vegetable product line to Seneca Foods Corporation. In connection with the sale, B&G Foods, which will retain ownership of the Green Giant trademarks, will license the Green Giant brand name to Seneca Foods. The sale does not include Green Giant frozen, Green Giant Canada or the Le Sueur brand. B&G Foods intends to use the net proceeds from the sale for the repayment of long-term debt. The terms of the transaction were not disclosed."

16:19 EST EnerSys wins 50 unit order for fast charge and storage system - EnerSys announced that Landmark Dividend LLC has placed an order for 50 units of EnerSys's proprietary and revolutionary energy storage and management systems which enables energy optimization through various applications including demand charge reduction, utility back-up power, and dynamic fast charging for electric vehicles (EVs). EnerSys's unique Fast Charge and Storage (FC&S) solution, provides energy management capability to enable customers to optimize their energy consumption by proactively managing energy demand to eliminate short-term peaks, taking pressure off the electrical grid, and reducing peak rate electricity surcharges. In addition, the system is controlled by sophisticated software, ensuring that it operates efficiently and allowing remote monitoring of its performance and reliability.

16:11 EST Sitio Royalties raises quarterly dividend to 49c per share - Declared 3Q 2023 dividend of $0.49 per share of Class A Common Stock, an increase of $0.09 per share, or approximately 23% relative to 2Q 2023

16:09 EST Koru Medical names Ken Miller chief commercial officer - Koru Medical Systems announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. "I am confident that Ken's experience in healthcare paired with his track record of success will be instrumental in propelling KORU Medical in this next phase of our growth. His arrival comes at an exciting time in our company's journey and his commercialization expertise, drive and passion for customers and innovation will be instrumental in achieving this next stage of our success," said Linda Tharby, KORU Medical's President and CEO. "I am grateful to have Ken's leadership on the KORU Medical team as we continue to grow the business in new markets and geographies and execute on our strategic growth plan."

16:09 EST Polestar Automotive announces 'strengthened' business plan - Polestar Automotive Holding UK presents a strengthened business plan which targets an accelerated margin improvement and a reduction of the Company's total funding need to the point of cash flow break-even in 2025. In light of a fast-changing operating environment, Polestar has introduced a strengthened business plan that reorients a path to profitability by prioritising margin progression over volume. For the fiscal year 2025, Polestar is targeting a gross margin in the high teens with a total annual volume of approximately 155,000-165,000 cars. This is expected to be achieved through a richer product mix, with four models in production, reduced cost structure and refocused approach to key markets including a new joint venture in China and measures to improve profitability in the US business. Polestar has already implemented cost reduction measures announced earlier this year around headcount reductions and continues to advance active cost management efforts. Showing their continued commitment to Polestar, Geely Holding and Volvo Cars have provided additional liquidity to the Company. Pursuant to an amendment to its existing shareholder term loan, Volvo Cars has extended the maturity of its outstanding term loan by over three years to June 2027, and provided an aggregate of $200 million in additional loan capacity with the same maturity date, bringing the total investment to $1 billion. In addition, Geely Sweden Automotive Investment AB is making available a $250 million term loan on substantially the same terms as Volvo Cars, including the maturity in June 2027. Both loans have an optional equity conversion feature. Based on the reduced funding need from a strengthened business plan and new and existing financing and liquidity support from Geely Holding and Volvo Cars, Polestar expects it will require external funding of approximately $1.3 billion until achieving cash flow break-even, targeted in 2025. Working alongside its major shareholders, Polestar is well-progressed on a holistic financing plan to provide the remainder of funding required, including additional debt and equity.

16:07 EST Polestar Automotive expects to deliver 60,000 vehicles this year - The company said, "We now expect to deliver approximately 60,000 vehicles for this year and a gross margin of approximately 2% for the full year."

15:50 EST MHRA authorizes diabetes drug Mounjaro for weight management - The United Kingdom's MHRA stated: "For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support weight loss." Reference Link

15:30 EST Mortgage applications increased 2.5% from last week, MBA says - Mortgage applications increased 2.5% from one week earlier, according to data from the Mortgage Bankers Association's or MBA Weekly Mortgage Applications Survey for the week ending November 3. The Market Composite Index, a measure of mortgage loan application volume, increased 2.5% on a seasonally adjusted basis from one week earlier. On an unadjusted basis, the Index increased 1% compared with the previous week. The Refinance Index increased 2% from the previous week and was 7% lower than the same week one year ago. The seasonally adjusted Purchase Index increased 3% from one week earlier. The unadjusted Purchase Index increased 1% compared with the previous week and was 20% lower than the same week one year ago. "The 30-year fixed mortgage rate dropped by 25 basis points to 7.61% , the largest single-week decline since July 2022," said Joel Kan, MBA's Vice President and Deputy Chief Economist. "Last week's decrease in rates was driven by the U.S. Treasury's issuance update, the Fed striking a dovish tone in the November FOMC statement, and data indicating a slower job market. Applications for both purchase and refinance loans were up over the week but remained at low levels. The purchase index is still more than 20 percent behind last year's pace, as many homebuyers remain on the sidelines until more for-sale inventory becomes available." Companies in the space include: Invesco (IVR) Rocket Companies (RKT), LendingTree (TREE), Discover (DFS Wells Fargo (WFC), Zillow (Z), Lennar (LEN) and Redfin (RDFN) . Reference Link

14:42 EST Royalty Management Holding Corp trading halted, volatility trading pause

13:21 EST Unique Fabricating trading halted, news pending

13:08 EST Sirius XM unveils new SiriusXM Streaming app, priced at $9.99 per month - At SiriusXM's Next Generation Industry & Press Preview, the company revealed its refreshed brand platform and identity - including a new logo, master color palette, and mascot - which it says "bring to life the company's brand proposition of bringing listeners closer to what they love." SiriusXM's updated brand accompanies the unveiling of the company's next generation Streaming app, new pricing, original programming, and more, the company added. The company unveiled the new SiriusXM Streaming app, rolling out to subscribers across North America beginning on December 14, and the newly-priced Streaming All Access Plan for $9.99 a month. "The introduction of the new SiriusXM streaming experience marks a pivotal moment in our history, one that kicks off a new era of innovation at our company. And this launch is just the beginning; we will continue to iterate and develop our product offerings throughout the next year and beyond as we strive to deliver our subscribers the best listening experience on the go, in the car, and wherever they choose to tune in. From can't miss live moments to the perfect soundtrack for any occasion, with the new SiriusXM, we are putting our differentiators at the forefront and welcoming in a new generation of listeners, bringing them closer to what they love," said Jennifer Witz, CEO, SiriusXM.

12:27 EST Eli Lilly confirms weight loss approval with list price of $1,059.87 - Eli Lilly (LLY) confirmed the Food and Drug Administration approved the company's Zepbound injection. Zepbound is indicated for adults with obesity or those who are overweight and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off, the company said in a statement. "It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis," Eli Lilly added. Zepbound is expected to be available in the U.S. by the end of the year in six doses at a list price of $1,059.87, which Eli Lilly says is approximately 20% lower than Novo Nordisk's (NVO) semaglutide 2.4 mg injection for weight loss.

12:22 EST Eli Lilly weight loss drug Zepbound approved by FDA - The Food and Drug Administration said it approved Zepbound injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol, for use, in addition to a reduced calorie diet and increased physical activity. Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro to be used along with diet and exercise to help improve blood sugar in adults with type 2 diabetes mellitus. The FDA said Zepbound's effectiveness for chronic weight management in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials of adults with obesity or overweight with at least one weight-related condition. The FDA granted the approval to Eli Lilly.

12:13 EST FDA posts approval of Eli Lilly weight loss drug Zepbound

12:00 EST Inspire Medical falls -16.6% - Inspire Medical is down -16.6%, or -$26.81 to $134.93.

12:00 EST Custom Truck One Source falls -25.5% - Custom Truck One Source is down -25.5%, or -$1.56 to $4.55.

12:00 EST James Hardie rises 16.6% - James Hardie is up 16.6%, or $4.39 to $30.91.

11:45 EST Global Mofy Metaverse Ltd trading resumes

11:32 EST Revolution Medicines, EQRx stockholders approve EQRx acquisition - Revolution Medicines (RVMD) and EQRx (EQRX), announced that, at their respective special meetings, Revolution Medicines and EQRx stockholders voted to approve Revolution Medicines' proposed acquisition of EQRx. The final votes will be certified by an independent inspector of elections for each company and publicly reported following this certification. The transaction is expected to close in November 2023, as soon as all customary closing conditions are satisfied. Upon completion of the transaction, each share of common stock of EQRx issued and outstanding immediately prior to the merger will be converted into the right to receive 0.1112 shares of common stock of Revolution Medicines. Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger. No fractional shares will be issued and EQRx stockholders will receive cash in lieu of any fractional shares as part of the merger consideration, as specified in the merger agreement.

11:06 EST ONR awards $5M contract to BAE Systems for COALESCE program - The Office of Naval Research has awarded BAE Systems' FAST Labs research and development organization a $5M contract for the COALESCE program. In this effort, BAE Systems' FAST Labs, will develop advanced Gallium Nitride-based monolithic microwave integrated circuit and module electronics. The program's objective is to develop the world's highest efficiency high power amplifier module in its frequency band. The radio-frequency modules will then transition to small form factor U.S. Navy payloads, enabling longer range and greater effectiveness in active electronic warfare applications.

11:03 EST Huntington Ingalls' Newport News division opens additional Norfolk site - HII's Newport News Shipbuilding division has begun production at an additional campus in Norfolk to support the shipyard's continued progress toward more effective and efficient shipbuilding. The Newport News Shipbuilding Norfolk Campus is located on land leased from Fairlead in the Lambert's Point area, at a development known as Fairwinds Landing. NNS shipbuilders have worked at the site for several months constructing steel panels that will eventually make up units of Gerald R. Ford-class aircraft carrier Enterprise. In addition to Enterprise panel production work, the site is freeing up critical storage space at the main shipyard in Newport News to support other programs, including nuclear-powered submarine production. The campus in Norfolk also allows for future growth opportunities.

10:39 EST ATI Physical Therapy trading resumes

10:34 EST Amcor, NOVA Chemicals enter agreement to source polyethylene - Amcor announced a Memorandum of Understanding with leading sustainable polyethylene producer NOVA Chemicals Corporation for the purchase of mechanically recycled polyethylene resin for use in flexible packaging films. Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity. NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, is projected to be in operation as early as 2025. The supply agreement would enable Amcor to purchase SYNDIGO rPE resin, manufactured at NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, which is projected to be in operation as early as 2025. The recycling facility was announced in July as a significant expansion of NOVA Chemicals' Circular Solutions business. NOVA Chemicals plans to expand its recycling footprint across North America over the next several years to help reach its industry-leading ambition of 30% share of total PE sales from products containing recycled content.

10:17 EST Mobiv Acquisition Corp trading resumes

10:07 EST Mobiv Acquisition Corp trading halted, volatility trading pause

10:01 EST Neptune Wellness increases Sprout ownership to about 89.5% via debt exchange - Neptune Wellness Solutions announced that it has effectively converted a substantial portion of Neptune's Sprout debt into Sprout equity for the company's organic baby and toddler food brand, Sprout Organics. In accordance with the terms of the previously announced exchange option, Sprout debt was exchanged for Sprout equity resulting in Neptune having increased Sprout ownership from 50.1% to approximately 89.5%.

10:00 EST Toast falls -17.1% - Toast is down -17.1%, or -$2.94 to $14.30.

10:00 EST Roblox rises 15.0% - Roblox is up 15.0%, or $5.25 to $40.32.

10:00 EST Local Bounti rises 43.9% - Local Bounti is up 43.9%, or $1.93 to $6.33.

09:47 EST Adient falls -13.6% - Adient is down -13.6%, or -$4.84 to $30.75.

09:47 EST Toast falls -17.4% - Toast is down -17.4%, or -$3.00 to $14.25.

09:47 EST Roblox rises 17.8% - Roblox is up 17.8%, or $6.24 to $41.31.

09:45 EST MSP Recovery Inc trading halted, volatility trading pause

09:32 EST Lexeo Therapeutics Inc trading halted, volatility trading pause

09:28 EST American Power granted U.S. patent for dual fuel-electrification hybrid solution - American Power Group announced that the U.S. Patent and Tradmark Office has granted patent number 11,766,944 titled Multi-Fuel, Range Extending Power Generation Propulsion System, Method, and Apparatus to the company.

09:15 EST Alfasigma completes acquisition of Intercept - Alfasigma and Intercept Pharmaceuticals announced the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes, Alfasigma acquired all remaining shares of common stock of Intercept through a merger pursuant to Section 251(h) of the General Corporation Law of the State of Delaware. As a result of the transaction, Intercept has become a wholly owned subsidiary of Alfasigma, and the common stock of Intercept has ceased to be traded on the NASDAQ Stock Market. At the effective time of the merger, and subject to any perfected appraisal rights, all of the remaining shares of common stock of Intercept not purchased in the tender offer were converted into the right to receive the same USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes. With this transaction, Alfasigma adds Ocaliva to its portfolio, the only second-line treatment approved by the Food and Drug Administration for primary biliary cholangitis, a progressive autoimmune disease affecting the liver. The deal will strengthen Alfasigma's pipeline, with the addition of a novel fixed-dose combination possibly establishing a new treatment paradigm for PBC.

09:13 EST Microbot Medical granted registered trademark from USPTO - Microbot Medical had been granted a registered trademark from the US Patent and Trademark Office. The trademark "One & Done" was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular procedures using the device. With this trademark, the Company continues to expand its proprietary assets, including numerous approved and pending patents all over the world, and differentiate its product's capabilities.

09:12 EST Replimune Group presents updated data on RP2 in uveal melanoma - Replimune Group announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab. The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia. Treatment with RP2 led to an overall response rate of 29.4 percent. including responses in patients with liver, lung, and bone metastases. The median duration of response at the data cutoff was 11.47 months. Nearly all patients in the study had progressed on or after immunotherapy with 12 of 17 patients having received both prior anti-PD1 and anti-CTLA-4 therapy, including four of the responding patients. The slides are available on our website under presentations. RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed. The most common grade 1 or 2 treatment related adverse events overall in both cohorts were pyrexia, chills, fatigue, hypotension and pruritis. Six patients had grade 3 TRAEs, including two cases of hypotension. There were no grade 4 or 5 TRAEs.

09:08 EST BK Technologies signs manufacturing, supply agreement with East West - BK Technologies has signed a manufacturing and supply agreement with East West Manufacturing to transition BK's West Melbourne, Florida manufacturing activities to East West's facilities. East West will become the exclusive manufacturer of the Company's radio product line. With the transition of its manufacturing operation to East West, the Company's West Melbourne facility will solely focus on new product introductions to support BK's engineering programs and customer repair services. Based in Atlanta, Georgia, East West is an integrated design, engineering, manufacturing, and distribution services partner for original equipment manufacturers and distributors throughout North America and Europe. It is a portfolio company of MSD Partners. Under the terms of the Agreement, East West will make, in aggregate, a $2,000,000 investment in the Company. This includes the purchase of 77,520 shares of BK at a price of $12.90 per share, representing an investment of $1,000,000. East West will also receive Warrants to purchase 135,500 shares of BK at a strike price of $15.00 per share. The Warrants have a term of five years from the issuance date. Manufacturing of BK Technologies products is expected to begin at East West during the first quarter of 2024 with the full operational transition expected to be completed within the ensuing six months. The move will take place in stages and BK Technologies is taking precautions to prevent any production or delivery delays associated with the factory transition.

09:06 EST LPL Financial: SYV Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Brad Sicoff CRPC and Bruce Porter CFP of SYV Wealth Advisors have joined LPL Financial's broker-dealer, RIA and custodial platforms. They are joined by their Director of Operations, Molly Ware. The team reported having served approximately $115 million in advisory, brokerage and retirement plan assets, and joins LPL from Cambridge.

09:05 EST Neuraxis signs exclusive option agreement with University of Michigan - NeurAxis announced it has executed an exclusive option agreement with the University of Michigan for the exclusive licensing of its innovative rectal expulsion device, RED. The RED redesigns the balloon expulsion testing workflow to directly simplify anorectal function testing downstream to any gastroenterologist's office. During the option agreement period, NeurAxis intends to evaluate the vast market potential for RED. "We are thrilled to announce this exclusive agreement with the University of Michigan as it potentially expands and fuels NeurAxis' adult GI focus," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "RED offers a significant market opportunity for NeurAxis as it has a Category I CPT Code and established reimbursement in place and targets the same clinical call points as IB-Stim(TM). Working with the University of Michigan, we plan to submit RED for FDA clearance under a 510(k) process with a target commercialization in 2024 and we expect to see meaningful revenues from RED beginning in 2024."

09:03 EST Movella reschedules Q3 earnings conference call - Movella Holdings rescheduled the release of its financial results for the third quarter and nine months ended September 30, 2023 to after market close on Monday, November 13, 2023. A conference call to discuss Movella's financial results and outlook will be held at 2:00 p.m. PT / 5:00 p.m. ET. The call will be hosted by Ben Lee, CEO and Steve Smith, CFO. Q&A with management will follow immediately after prepared remarks.

09:02 EST PharmAla Biotech partners with Clariti Strategic Advisors - PharmAla Biotech Holdings signed an exclusive long-term agreement with Clariti Strategic Advisors of Toronto, pursuant to which Clariti will provide strategic advisory and investment banking services to the Company. Clariti will provide advice to help PharmAla ensure that its long-term value to its stakeholders is at all times being considered and optimized. Clariti, its subsidiaries and sub-agents will also advise as needed on: the raising of capital through strategic investments at the corporate or subsidiary/joint venture level, significant/strategic investments by PharmAla, joint venture arrangements, mergers and acquisitions, and the negotiation of strategic customer licensing or supply agreements. In connection with Clariti's engagement, the Company has issued Clariti: 2,300,000 stock options; and 2,300,000 restricted share units, pursuant to the Company's Option plan and RSU plan, respectively. Each Option is exercisable at a price of $0.175 per common share, expires ten years from the date of grant and vests only if there is, and prior to, a liquidity event.

09:01 EST Taoping awarded RMB15M contract - Taoping announced the company was awarded a RMB15M contract to provide integrated, cloud-based data analytics services to Shenzhen Chuangzhi Tiancheng Tech Co Ltd. to facilitate the intelligent operation and management of its mining project located in Northwest China, while greatly improving operating efficiency and safety.

09:00 EST Warner Bros. Discovery global DTC subscribers decreased 0.7M to 95.1M - Global DTC subscribers decreased 0.7M to 95.1M at the end of Q3 vs. 95.8M subscribers at the end of Q2. Global DTC ARPU was $7.82, a 6% ex-FX increase vs. the prior year quarter, Warner Bros. Discovery reported.

08:52 EST Apollo Global to offer senior notes - Apollo has commenced an offering of its senior notes, subject to market and other conditions. The notes will be fully and unconditionally guaranteed by Apollo Asset Management, Inc., Apollo Principal Holdings I, L.P., Apollo Principal Holdings II, L.P., Apollo Principal Holdings III, L.P., Apollo Principal Holdings IV, L.P., Apollo Principal Holdings V, L.P., Apollo Principal Holdings VI, L.P., Apollo Principal Holdings VII, L.P., Apollo Principal Holdings VIII, L.P., Apollo Principal Holdings IX, L.P., Apollo Principal Holdings X, L.P., Apollo Principal Holdings XII, L.P., AMH Holdings L.P. and Apollo Management Holdings. Apollo intends to use the proceeds from the offering to repurchase, repay, redeem or otherwise retire in full the $500 million aggregate principal amount outstanding of the 4.000% Senior Notes due 2024 issued by AMH before or upon their maturity and pay related fees and expenses. BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and RBC Capital Markets, LLC are acting as joint book-running managers. The offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.

08:42 EST DSS announces Impact BioMedical effected a 1-for-55 reverse stock split - DSS announced that Impact BioMedical filed a Current Report on Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing that Impact effected a reverse stock split of its issued and outstanding common stock by a ratio of 1 for 55. Impact did not effectuate a reverse split of its authorized capital stock and no amendment to the articles of incorporation or bylaws was made. Impact received approval from its majority stockholder and the Company's Board of Directors to effectuate the reverse split. In addition to the reverse split, Impact's Form 8-K discloses DSS BioHealth Security, Inc.'s, conversion of substantially all of its 87.5% common stock equity interest in Impact into an equivalent number of Series A Convertible Preferred Stock. DBH has voluntarily removed itself from receiving any future dividends from earnings, enhancing greater return potential to the remaining Impact common stock equity holders, as currently only the holders of common of Impact are eligible for any potential dividend distributions. Frank Heuszel, CEO of DSS, Inc., said, "By converting DBH's common equity interest into preferred stock, Impact has increased value for Impact's existing shareholders and the loyal DSS, Inc. shareholders who received the Impact shares through a dividend distribution."

08:39 EST Twin Vee PowerCats to move Aquasport production to Florida facility - Twin Vee PowerCats announced a strategic consolidation of its operations by moving the manufacturing of Aquasport products from Tennessee to its Fort Pierce, Florida facility. According to the Company, the decision is driven by the desire to increase efficiency and implement cost-saving initiatives throughout its brands. Twin Vee's Fort Pierce factory is currently in the process of expanding its floor space by approximately 30,000 square feet, increasing the total area of its boat-building facility to nearly 100,000 square feet of production space. The Company plans to add another manufacturing line to increase its production output once the expansion is completed. Despite the change, the Company continues to lean heavily into developing new Aquasport products to broaden the brand's appeal. According to Visconti, Aquasport will soon introduce a 24-foot center console boat and a 28-foot center console boat to Aquasport's model lineup.

08:38 EST Cellebrite equips investigators with next generation cloud-based solution - Cellebrite DI announced Cellebrite Smart Search, a new SaaS-based solution that securely automates the collection and review of publicly available online data. Gathering data manually from open sources, especially social media platforms, is time-consuming and often complex, and surfacing actionable insights from this data can be equally challenging. Smart Search can save investigators hours of work. Available now, Smart Search is Cellebrite's next generation of open-source intelligence offerings. "Smart Search represents another powerful, new cloud-based offering from Cellebrite to help both digital forensic units and investigative units modernize their workflows," said Ronnen Armon, Cellebrite's Chief Products and Technology Officer. "This intuitive investigative solution is an important addition to our portfolio of digital intelligence offerings, enabling our law enforcement customers to work smarter and faster to address the major challenges impacting their organizations - from coping with rising data volumes and complexity, and modernizing inefficient operational processes to ensuring teams operate with the highest standards of ethics and accountability."

08:38 EST Safety Shot is official title sponsor of Save our Musicians foundation event - Safety Shot announced it is the official title sponsor of Save our Musicians event, "A Special Private Evening with Luke Bryan", a charity concert event on November 18, 2023 in Jupiter, Florida. Country superstar and American Idol judge Luke Bryan will be performing to raise money for the arts in public schools. This concert follows a similar successful Save our Musicians fundraiser featuring Gwen Stefani which also raised funds for arts education and garnered over 3 million views on social media. "We are so proud to sponsor this charity event, right in Safety Shot's home town in Jupiter, Florida. Luke Bryan, a country music icon, represents the best of America. We look forward to introducing Safety Shot to concert-goers at the upcoming event and believe Safety Shot will appeal to Luke's fans across the U.S. who may view the concert across digital platforms," stated Safety Shot's CEO Brian John.

08:37 EST NRSInsights says October same-store sales increased 3.2% - NRSInsights announced comparative same-store sales results for October 2023. As of October 31, 2023, the NRS retail network comprised approximately 27,200 active terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, and tobacco and sundries sellers nationwide, predominantly serving urban consumers. Retail Same-Store Sales Highlights Same-store sales in October 2023 increased 3.2% from a year earlier. Average sales per calendar day for October 2023 decreased 2.1% compared to the preceding month. Same-store sales in the preceding month had increased 6.1% compared to the year-ago month. Average sales per calendar day in September 2023 had increased 1.7% compared to the preceding month. For the three months ended October 31, 2023, same-store sales increased 4.8% compared to the three months ended October 31, 2022. The number of items sold during October 2023 increased 4.1% compared to October 2022 but decreased 0.9% compared to September 2023 on a per calendar day basis. The average number of transactions per store in October 2023 increased 2.8% compared to October 2022. The average number of transactions per calendar day in October 2023 decreased 1.6% compared to September 2023. A dollar-weighted average of prices for the top 500 items purchased in October 2023 increased 1.6% year-over-year, a decrease from the 5.3% year-over-year increase recorded in September 2023.

08:33 EST Global Payments announces appointment of Shannon Johnston as CIO - Global Payments announced the appointment of Shannon Johnston, currently executive vice president, chief digital officer and deputy chief information officer, to senior executive vice president and chief information officer, effective January 1, 2024. Guido Sacchi, senior executive vice president and chief information officer, will retire at the end of 2023 after nearly 13 years with the company. Sacchi will continue to serve as a strategic advisor to the company, assisting with transition through February 2024. "Guido is a highly regarded, exceptional leader who has been instrumental in the transformation of our company into the payments technology and software leader we are today," said Cameron Bready, president and chief executive officer, Global Payments. "Guido is not only a trusted partner, but a friend, and I greatly admire his accomplishments during his long tenure at Global Payments. He leaves behind a legacy and will be missed by the entire leadership team and his technology colleagues around the world. I wish Guido and his family all the best in his retirement."

08:21 EST Biomerica expands inFoods IBS reach with addition of several new GI groups - Biomerica announced that several new Gastrointestinal groups have signed up and begun using the Company's revolutionary inFoods IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for Irritable Bowel Syndrome while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company's first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.

08:20 EST Endra Life Sciences portfolio increases to 70 issued patents - The following three patents were issued: U.S. Patent No. 11806113, titled "Thermoacoustic Probe," relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge. This builds upon ENDRA's U.S. Patent No. 11730374, which defines and protects ENDRA's integrated wedge technology. Chinese Patent No. ZL 2021800299011 titled "Thermoacoustic Transducer with Integrated Switch," relates to a novel system for reducing false signals in thermoacoustic imaging. ENDRA expects the '011 patent to be effective for all thermoacoustic imaging applications. The Chinese '011 patent is related to its parent patent, U.S. Patent No. 11172829. Chinese Patent No. ZL 2022800094336 , titled "Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture," protects ENDRA's proprietary manufacturing process to acoustically isolate the radiofrequency element from the transducer element. The Chinese '336 patent is related to its parent patent, U.S. Patent No. US10996163. "Our IP portfolio has reached a new milestone of 70 issued patents globally. We believe this is a remarkable achievement for a company of our size and a testament to the innovation of ENDRA," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "These newly issued patents protect and further differentiate ENDRA's thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease."

08:17 EST Janover enters strategic referral partnership with La Rosa Holdings - Janover (JRVR) has entered into a strategic referral partnership agreement with La Rosa Holdings Corp. (LRHC). La Rosa operates an end-to-end real estate services platform specializing in residential and commercial real estate brokerage and will introduce Janover to clients looking to secure a commercial loan.

08:16 EST GE HealthCare, Masimo team to bring SE Pulse Oximetry to mobile platform - GE HealthCare (GEHC) and Masimo (MASI) announced a joint agreement to integrate Masimo Signal Extraction Technology SET pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution. Portrait Mobile is built as an Internet of Medical Things IoM platform, using the latest cloud native technology to provide an end-to-end experience for wearable continuous monitoring. By integrating Masimo SET clinicians will be able to leverage Masimo's clinically proven Measure-through Motion and Low Perfusion oxygen saturation SpO2 measurement technology to noninvasively detect and continuously monitor changes in patient status. The agreement follows Portrait Mobile's 510(k) clearance from the U.S. FDA in August 2023. .."We are excited to build on our collaboration with GE HealthCare by providing integrated solutions to help our customers and optimize patient care," said Bilal Muhsin, Chief Operating Officer at Masimo. "Through our expansion into mobile, wireless technologies, we are proud to incorporate Masimo SET(R) pulse oximetry into the Portrait Mobile monitoring solution."

08:15 EST Metals Company provides additional details on offshore campaign - The Metals Company provides additional details on the previously announced offshore campaign to revisit the site of last year's nodule collection system test conducted by its subsidiary, Nauru Ocean Resources, with the objective to assess seafloor impacts and recovery rates twelve months after the test. The Company expects to commence the campaign in Q4 2023. Researchers plan to return to the NORI-D area in the Clarion Clipperton Zone to collect further environmental data for NORI's application for an exploitation contract, which it expects to submit following the July 2024 meeting of the International Seabed Authority, as well as to inform its Environmental Management and Monitoring Plan. Specialized research teams will use an array of boxcore and multi-core samplers as well as various benthic lander systems to assess impacts to biota and ecosystem function on the seafloor in NORI-D.

08:15 EST Chipotle names Ilene Eskenazi as Chief Human Resources Officer - Chipotle Mexican Grill (CMG) announced that it has hired Ilene Eskenazi as its Chief Human Resources Officer. Serving on the Executive Leadership Team, Eskenazi will begin on November 27, and report to Chairman and CEO Brian Niccol. Eskenazi comes to Chipotle from Petco Health and Wellness Company (WOOF), where she served as Chief Legal and Human Resources Officer, overseeing compensation and benefits, human resources operations, talent management, as well as all legal matters.

08:13 EST Silo Pharma to initiate dose-ranging study of SPC-15 - Silo Pharma announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range. In collaboration with AmplifyBio, Silo Pharma's contract research organization partner, the six- to eight-week non-good laboratory practice study will include single ascending dose evaluation and a 7-day repeat intranasal dose toxicity and pharmacokinetic study. The final validation report is expected in 2024. "Determining the dose range that should be studied is an important step before taking a new drug candidate into a first-in-human trial," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "Completion of this study, along with our recently announced human factor study, is expected to give us an early start on our goal of a Phase 1 clinical trial of SPC-15."

08:13 EST Vishay to acquire Nexperia's Newport water fab for $177M in cash - Vishay Intertechnology and Nexperia B.V. announced that they have entered into an agreement that Vishay will acquire Nexperia's wafer fabrication facility and operations located in Newport, South Wales, U.K. for approximately $177M in cash. ATREG, Inc., the Seattle-based premier global firm for initiating, brokering, and executing the exchange of semiconductor manufacturing assets, served as Nexperia's transaction advisors. "Under new leadership in early 2023, Vishay set an ambitious goal of investing approximately $1.2 billion in capacity over a three-year period in order to position the company to seize the opportunities created by the megatrends of e-mobility and sustainability needed for a Net Zero economy. While this transaction is supplemental to our capex investment strategy, adding Newport Wafer Fab to our manufacturing footprint will be instrumental to achieving our goal of expanding capacity for our customers and to accelerating our SiC strategy," said Joel Smejkal, President and CEO of Vishay.

08:12 EST Organovo highlights FXR314 combination therapy potential, plan - Organovo announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the data it can generate can be powerful in establishing a strong use case for FXR314 in patients, and provide support for collaborations with major pharmaceutical companies currently offering IBD treatments. The differentiated mechanism of action of FXR314 provides substantial promise that the drug's impact will strongly complement the biology of other successful drugs in the space, e.g. TNF-alpha inhibitors, IL-12/23 inhibitors, and JAK inhibitors. In both Organovo's proprietary 3D human models and in preclinical animal models of disease, FXR314 treatment demonstrates a reduction in the disruption of the intestinal lining, which protects against bacteria penetrating into the intestinal wall. Further, our models and published literature indicate a role of FXR314 in modulating responses in innate lymphoid cells in the intestine, preventing the cytokine release that triggers a systemic immune-inflammatory response. "We remain excited about the potential of FXR314 to treat IBD due to its unique mechanism of action, and about our upcoming Phase 2 study to demonstrate its activity in ulcerative colitis," said Keith Murphy, Organovo Executive Chairman. "As we enroll patients and complete the Phase 2, we are eager to explore the drug's potential for combination therapy and share our findings and the opportunities we see to further benefit patients, some of whom don't benefit from existing therapies due to safety limitations or low response rates. There remains great unmet need in inflammatory bowel disease, and we look forward to defining multiple roles FXR314 can play in providing treatment solutions."

08:10 EST REALLY selects Optiva to help launch wireless service - Optiva has been selected by REALLY to power and grow its new mobile phone service nationwide, powered by Optiva BSS on Google Cloud. REALLY is on a mission to bridge the digital divide by introducing a nationwide decentralized wireless network across the U.S., commencing in Austin, Texas.

08:09 EST Aclarion announces it enrolled ten KOLs to assist with Nociscan - Aclarion announced that they have successfully achieved their goal of enrolling ten leading spine surgery KOLs to assist the company in driving Nociscan to standard of care for identifying discogenic low back pain. "Since executing our IPO last year, Aclarion has consistently achieved catalysts of value creation that fall into a very concise framework of technology readiness, clinical evidence, and surgeon advocacy that are proven to bring disruptive technological advancements to standard of care in the healthcare sector," said Brent Ness, Chief Executive Officer of Aclarion. "The steps we have taken in a short timeframe demonstrate that our actions follow our stated intentions. We are incredibly proud of the KOL panel that has rallied to help bring Nociscan to standard of care."

08:09 EST Perspective announces first patient dosed in Phase 1/2a study of VMT-a-NET - Perspective Therapeutics announced that the first patient was dosed at Washington University in St Louis in the Company's Phase 1/2a trial evaluating the safety and efficacy of [212Pb]VMT-alpha-NET, a targeted alpha-particle therapy, in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. The trial is a multi-center, open-label dose escalation, dose expansion study of VMT-alpha-NET in patients who have not received prior peptide receptor radionuclide therapy. "We are proud of our team's commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors," said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics. "Based on the promising clinical data observed in the investigator-led study in India that was presented at the recent European Association of Nuclear Medicine meeting, we believe VMT-alpha-NET has the potential to provide significant improvements in clinical outcomes compared to standard of careDOTATATE. With our FDA Fast Track Designation for first-line treatment in all neuroendocrine tumors, we plan to rapidly advance this product through clinical development."

08:07 EST Assembly Biosciences names Gaggar as Chief Medical Officer - Assembly Biosciences announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus, hepatitis C virus and hepatitis D virus infections. Dr. Gaggar joins from Arrive Bio, a private early-stage biotechnology company that he co-founded and served as chief executive officer.

08:06 EST Posco, Invest Alberta sign MOU to further ventures in the region - POSCO Holdings and Invest Alberta formalized a partnership by signing a memorandum of understanding to further the company's ventures in Alberta. As part of the agreement, POSCO Holdings is considering investing in the exploration, development, and commercialization of lithium in Alberta. POSCO Holdings will commence exploring prospects in a region that presents a significant opportunity in the global critical minerals competition.

08:03 EST Apollo Global to host Platform Origination Deep Dive - Apollo will host an informational session for the investment community on Tuesday, November 14, 2023, detailing its Platform Origination strategy. This "Deep Dive" will feature a series of presentations from Apollo's Co-Head of Global FIG, Chris Edson, Chief Financial Officer, Martin Kelly, and senior leaders of Apollo's platform businesses. These leaders will outline Apollo's views on the evolving private credit landscape, provide new insights into its differentiated asset origination ecosystem, and translate how Apollo believes this opportunity drives increasing earnings power for shareholders.

07:53 EST Amazon announces new health care benefit to Prime members via One Medical - "As part of its effort to make it easier for customers to get and stay healthy, Amazon announced a new Prime membership benefit that brings high-quality care from One Medical to Prime members. It's a health care experience designed around customers, with a care team that's on call and ready for members when and where they need them. One Medical, an Amazon company, has been reinventing the health care experience to make it easier for people to get the health care they need-from preventive care, to addressing immediate concerns, to managing chronic conditions like diabetes. Nationwide On-Demand Virtual Care 24/7 at No Additional Cost: The One Medical membership covers unlimited access to 24/7 on-demand virtual care, including video chats with licensed providers within minutes and an easy in-app "Treat Me Now" feature that lets members get fast care for common concerns like cold and flu, skin issues, allergies, urinary tract infections, and more. Virtual care is available nationally, and members don't incur any additional costs for on-demand virtual care services-it's all covered by the membership. And One Medical's app makes it easy for members to navigate care and stay on top of their health journey-from prescription management, secure messaging with providers, follow-up action items after appointments, and more," said the company in a statement.

07:47 EST Dundee Precious Metals appoints Robert Bosshard to board - Dundee Precious Metals appointed Mr. Robert Bosshard to the Board of Directors of DPM, effective December 1, 2023. Prior to retiring as partner in 2016, he had a multi-decade career with PricewaterhouseCoopers, both in Canada and the United Kingdom.

07:45 EST Signal Gold receives results of VLF electromagntic survey at Goldboro - Signal Gold announced that it has received the results of a 2,700-line kilometre airborne magnetic and very low frequency electromagnetic survey over its extensive land position in the Goldboro Gold District in Nova Scotia, which includes the Goldboro Project. VLF anomalies are known to form distinct, linear conductive-high response closely aligned with mineralization along the Goldboro Trend, and specifically the Goldboro Deposit. The results of the airborne survey indicate numerous VLF anomalies associated with both the Goldboro and Lower Seal Harbour Trends, a combined 51 kilometers of strike potential, including areas with little to no previous exploration work. Based on the high-resolution magnetic and VLF data sets, the Company has initiated a geological mapping and prospecting program to further refine and test new targets and develop detailed exploration plans to ultimately drill test the highest priority targets. The airborne survey was designed to cover the entirety of the Company's recently expanded land position comprising approximately 19,450 hectares of prospective mineral exploration licences, with particular focus on the 28-kilometre strike length along the Upper Seal Harbour Anticline and the 23-kilometre strike length along the Lower Seal Harbour Anticline. The survey was completed by Terraquest Ltd. and comprised high-resolution aeromagnetics, horizontal gradiometer and matrix digital VLF electromagnetics. The survey was flown at 100 metre north-south line spacing with one kilometre tie lines. Compilation of historic geophysical data by the Company indicates that VLF forms a distinct, linear conductive-high response that is closely aligned with the hinge of the host anticline along the Goldboro Trend, including the host structure of the Goldboro Deposit. The Company has used this historic data, in conjunction with recent ground Induced Polarization surveys, to construct a robust model for regional exploration targeting. This model has proved successful in our recent drilling west of the current resource model and towards the past producing Dolliver Mountain Gold Mine* where multiple gold bearing quartz veins have been intersected.

07:44 EST Bombardier brings Global 7500, Challenger 3500 jets to Dubai Air Show - Bombardier announced that its industry-leading Global 7500 and Challenger 3500 aircraft will be on display during the Dubai Air Show Nov. 13-17 in Dubai, UAE revealing the uncompromising attributes of these business jets. Bombardier is also pleased to share that it will have a presence on site, with sales teams from business aircraft and Bombardier Defense. "We are pleased to be bringing the uncompromising Challenger 3500 and Global 7500 aircraft to the Dubai Air Show this year, celebrating the Global 7500's recent 150th built aircraft and impressive new speed records*," said Eric Martel, Bombardier's President and Chief Executive Officer. "The Middle East is an important market for Bombardier both for business jet customers as well as growing defense business. The Bombardier team on site will proudly showcase our impressive defense capabilities and the many multi-mission solutions we can flexibly tailor. We also look forward to showcasing our Challenger and Global platforms to business jets customers, who will benefit from our aircraft cutting-edge innovation, cabin design, performance, reliability and smooth ride.

07:43 EST HCW Biologics announces results from ongoing Phase 1 trial of HCW9218 - HCW Biologics announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. Data from this study was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, SITC. This clinical readout was based on 15 patients who were enrolled in the study as of October 16, 2023, all of whom were patients whose disease had previously progressed after multiple lines of standard-of-care therapy. The trial is now in its final expanded dose level, and the Company expects it to be completed in the fourth quarter of 2023. There has been one dose-limiting toxicity experience in this study, but it did not trigger stopping rules. Highlights of data presented at SITC include: HCW9218 was administered subcutaneously once every three weeks for up to six cycles at dose levels 0.25 mg/kg, 0.5 mg/kg, 0.8 mg/kg or 1.2 mg/kg. The median number of cycles was three. 87% had greater than4 lines of prior therapy. 53% patients treated with HCW9218 were evaluated in a post-treatment assessment, including biopsies and scanning. 50% patients evaluated in post-treatment assessments exhibited stable disease following HCW9218 treatment. Patients showed stable disease lasting over 6 months. Clinical benefit was observed from DL2, DL3 and DL4. 66% patients with ovarian cancer who underwent post-treatment assessments showed stable disease. Analysis of patients' pre- and post-treatment blood and tumor biopsy specimens revealed that HCW9218 induced National Killer cell and CD8+ T cell activation, proliferation, and infiltration into the tumor microenvironment which correlated with disease stabilization. Repeated HCW9218 administration at up to the highest planned dose level was well tolerated by patients with chemotherapy-refractory advanced solid tumors, which has provided support for the Recommended Phase 2 Dose level for future Phase 2 studies of HCW9218. HCW9218 significantly reduced blood levels of TGF-beta in cancer patients in a dose-dependent manner, without causing treatment-emergent skin lesions and bleeding events previously reported with TGF-beta antagonists in clinic. HCW9218 strongly promotes proliferation and activation of NK and T cells in patients' blood after dosing without causing cytokine release syndrome. No liver enzyme elevation was observed. HCW9218 also showed a substantial increase in blood NK cell counts three weeks after a single dosing.

07:41 EST Applied UV's Sterilumen launches new air, HVAC disinfection solutions - Applied UV announced its participation at the Gulfood Manufacturing event underway in Dubai, November 7-9. This event is the preeminent food security trade show in the region, and Sterilumen is exhibiting along with its partner, Batta Environmental. Sterilumen has unveiled two new pioneering solutions aimed at revolutionizing food safety and preservation standards in the region during the event: The Airocide Pro: Developed in collaboration with Canon USA, a global manufacturing powerhouse, the Airocide Pro represents the next generation of air disinfection technology. PURO HVAC solutions: Following the recent acquisition of PURO Lighting, Sterilumen will be displaying the patented Fighter Flex coil disinfection system under PURO HVAC solutions.

07:37 EST Red Cat's Teal Drones selected for $750K manufacturing grant from Utah - Red Cat announcesthat its subsidiary Teal Drones has been selected to receive a $750,000 Manufacturing Modernization Grant from the State of Utah. This grant will help expand Teal's manufacturing capability and ensure that both existing and future vertically integrated products will be manufactured in Teal's South Salt Lake facility. "We're grateful to the State of Utah and the Governor's Office of Economic Opportunity for selecting Teal as a recipient of this grant," said George Matus, Teal founder and CEO. "This is a big step toward rebuilding America's drone industrial base and expanding manufacturing on domestic soil. Drones are critical to the future of Defense and Teal is positioned to fulfill the exponentially growing demand from America and its allies."

07:36 EST Cronos Group reiterates operating expense savings target $20M-$25M - The Company reiterates its previously announced operating expense savings target of $20 to $25 million in 2023, and planned incremental operating expense savings of $10 to $15 million in 2024 primarily driven by savings in sales and marketing, general and administrative, and research and development. The organizational and cost savings initiatives are intended to position the Company to drive profitable and sustainable growth over time. Cronos anticipates that the net change in cash, defined as the sum of cash and cash equivalents and short-term investments, will decline by less than $5 to $10 million in the last three months of fiscal year 2023. The Company maintains its expectation that the net change in cash will be positive in 2024.

07:32 EST Greif reaffirms 2023 adjusted EBITDA view $790M-$820M - Greif reaffirms that fiscal 2023 results will be within the previously provided guidance range of Adjusted EBITDA of $790 million to $820 million in anticipation of participation in the Baird Global Industrial Conference in Chicago, IL on Wednesday, November 8, 2023.This guidance reaffirmation is attributable to performance in-line with expectations for the fiscal fourth quarter in both Paper Packaging & Services and Global Industrial Packaging. GIP volumes remained soft in all regions and most end markets during the quarter, with no positive volume inflections through October; the GIP business also faced a less favorable price / cost dynamic in Q4 as falling steel costs and the continued volume softness pressured margins. The PPS business experienced continued converting and mill volume weakness, both down mid-single digits year-over-year through the fourth quarter despite improved containerboard volumes in October, in addition to sequentially lower published RISI pricing and rising OCC costs.

07:29 EST Integra Resources files technical report for updated MRE at DeLamar - Integra Resources announced that it has filed a technical report for the updated Mineral Resource Estimate at the DeLamar and Florida Mountain Project located in southwestern Idaho. The MRE incorporates the results from the highly successful stockpile drill program completed in April 2023. The stockpile drill program added an Indicated resource of 504,000 ounces gold equivalent and an Inferred resource of 46,000 oz AuEq. Subject to further economic studies, the mineralized stockpile and backfill material that was incorporated into the updated MRE demonstrates the potential for this material to significantly increase the heap leach mine life in future production phases. The updated MRE increased the total heap leachable oxide-and-mixed ounces within the Measured and Indicated category by ~25% and increased the total Inferred ounces by ~31%. In total, ~90% of the updated MRE falls within the M&I category, highlighting the quality and scarcity of projects such as DeLamar in the prolific Great Basin mining district of the USA. DeLamar Technical Report Highlights: Including the 2023 DeLamar MRE, Integra now controls a total M&I resource of 6.2 million ounces AuEq and a total Inferred resource of 0.9Moz AuEq across its key projects located in Idaho and Nevada, representing one of the largest resource endowments in the Great Basin of the USA not controlled by a major mining company. Stockpile & Backfill Resource Update: The maiden stockpile resource estimate contains an Indicated resource of 504 thousand ounces AuEq at 0.37 grams per tonne AuEq, including 296koz gold and 16.1Moz silver and an Inferred resource of 46koz AuEq at 0.30 g/t AuEq, including 26koz Au and 1.5Moz Ag. The Company allocated a total of ~US$4.6 million to the stockpile drill program which successfully resulted in the addition of greater than500kozs AuEq, representing the lowest discovery cost per ounce in the history of DeLamar. A portion of the mineralized stockpile and backfill material was moved as a pre-stripping cost in the 2022 Pre-feasibility Study, however this material is expected to be processed in future economic studies. The stockpile and backfill material is also expected to reduce the overall mining cost as the material is located at surface and was previously mined, reducing or eliminating additional blasting costs. Total DeLamar and Florida Mountain Resource Update: The total DeLamar M&I resource contains 4.8Moz AuEq at 0.60 g/t AuEq, including 2.9Moz Au and 142.7Moz Ag. The total DeLamar Inferred resource contains 621koz AuEq at 0.45 g/t AuEq, including 428koz Au and 15.0Moz Ag. Oxide-mixed Heap Leach Resource Update: The oxide and mixed heap leach portion of the M&I resource contains 2.6Moz AuEq at 0.50 g/t AuEq, including 1.6Moz Au and 73.9Moz Ag. The oxide and mixed heap leach portion of the Inferred resource contains 284koz AuEq at 0.36 g/t AuEq, including 199koz Au and 6.6Moz ounces Ag. The significantly increased oxide and mixed resource at DeLamar demonstrates the potential for an extended heap leach mine life in future phases of operations. The Company anticipates filing the Mine Plan of Operations for DeLamar in Q4 2023, making DeLamar one of the only precious metal development projects in the Western United States that is actively being advanced towards a production permit.

07:27 EST Alterity Therapeutics completes enrollment in ATH434-201 Phase 2 - Alterity Therapeutics announced it has successfully completed enrolment in its ATH434-201 Phase 2 clinical trial. ATH434-201 is a randomized, double-blind, placebo-controlled study in patients with early-stage multiple system atrophy conducted across the U.S., Europe, Australia and New Zealand. "Completing enrolment in our ATH434-201 clinical trial in MSA is a significant milestone for Alterity as we look to bring a new oral therapy to people living with this devastating disease," said David Stamler, M.D., Chief Executive Officer of Alterity. "Due to the great clinical need and physician interest in our novel approach to address the underlying pathology of MSA, we exceeded our enrolment target. With our trial now fully enroled, study treatment will conclude in the fourth quarter of 2024 and the results from the trial will clarify the path forward for potential approval of ATH434."

07:26 EST James River Group to sell casualty reinsurance business to Fleming - James River announced that it has entered into a definitive agreement to sell JRG Reinsurance Company, its third-party casualty reinsurance business, to Fleming Intermediate Holdings. The total estimated transaction value is $277 million, inclusive of a $139 million pre closing dividend and a $138 million cash payment from Fleming at close. Under the terms of the transaction, valued as of September 30, 2023, James River would receive 0.75x the book value of JRG Re at closing. The transaction includes the full insurance entity supporting the Company's Casualty Reinsurance segment, including the remaining assets and liabilities, as well as the staff supporting the business. The segment produced $85.2 million of gross written premiums in 2022. Frank D'Orazio, the Company's Chief Executive Officer, commented, "Today's announcement represents a key milestone for James River and is strategically significant for both our Company and Fleming. The transaction aligns with James River's strategy to focus our resources on core businesses where we have meaningful scale, including our E&S and fronting businesses. We are excited about the new partnership with Fleming, which we believe will be a great new home for the staff of JRG Re." The transaction has been unanimously approved by the Board of Directors of both companies. It is subject to customary closing conditions including receipt of required regulatory approvals. It is expected to close during the first quarter of 2024.

07:24 EST LCI Industries narrows RV shipment outlook for FY23 to 295K-305K from 290K-310K - The company stated in a conference call yesterday: "We expect Q4 2023 RV shipments will be between 55,000 and 65,000 units with the full year estimated range of 295,000 to 305,000 units. Overall, we are expecting a 10% sequential decline in total revenue Q4 versus Q3 with aftermarket seasonally dropping about 15% sequentially. We are projecting positive net income in Q4 along with positive net cash flow from operations. Looking ahead to full year 2024, we expect RV wholesale shipments to be in the range of 325,000 to 350,000 units and the marine industry to continue to experience softness. The key takeaway for 2024 is that we will continue to grow the aftermarket and adjacent businesses while the RV industry slowly recovers. We believe Lippert is well equipped with the right strategy in place to maintain long term profitability and value for our shareholders."

07:24 EST Algernon Pharmaceuticals receives notice of allowance for Japanese patent - Algernon Pharmaceuticals has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled "Compositions and Methods for Treating Non-Alcoholic Steatohepatitis" with NP-251. The invention claims treating nonalcoholic fatty liver disease, including nonalcoholic steatohepatitis and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company was recently issued a patent from the US patent office for Repirinast in NASH and has also filed corresponding patent applications in Canada, Europe, and China. The company previously disclosed that Repirinast, in a widely used STAM mouse model of NASH from SMC Laboratories: Reduced hepatic fibrosis by 57% compared to vehicle; Reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31% compared to vehicle; In the same model, telmisartan, a positive control and the standard of care for NASH, reduced fibrosis by 27%; Repirinast is also the Company's lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction mouse model. Because patients with NAFLD have a two-fold increased risk of CKD, even when controlling for other comorbidities such as obesity, type 2 diabetes mellitus and insulin resistance, Repirinast is a strong candidate for both indications. Algernon's intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms.

07:19 EST Moderna to unveil AI, digital strategy at second Digital Investor Event - Moderna will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off its Manufacturing and Digital Day hosted in March 2020, the Company will showcase how AI continues to transform the organization and enhance its value creation. Today's presentation will highlight Moderna's leading position in AI-powered innovation, its ability to harness the power of AI to improve efficiency and scalability across the value chain, and its development of an AI-centric culture. "Just as the personal computer changed the way we work and live, AI will completely transform our everyday lives. At Moderna, we are leading the charge of this AI revolution in medicine. It is as much about technology as it is about people and ensuring they have the right skills," said Stephane Bancel, Chief Executive Officer of Moderna. "We were built on the premise that the natural flow of information in life, mRNA, can be used to develop transformative medicines, and by embedding AI into every aspect of how we work, we are accelerating our mission to deliver the greatest possible impact to people through mRNA medicines."

07:15 EST Cullinan Oncology expects cash to provide runway into 2H26 - Cash, cash equivalents, investments, and interest receivable were $481.9 million as of September 30, 2023. Cullinan now expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The extension from prior guidance is primarily driven by the receipt of approximately $38 million in net proceeds from Cullinan's ATM equity program, increased interest income, and the prioritization of development plans in the longer term. Cullinan's operating plan includes continued advancement of all programs to key data milestones in the near term.

07:10 EST Everi Holdings updates FY23 outlook - Everi updated its outlook for 2023 and now expects Adjusted EBITDA for the full year 2023 to be in line with the prior year. Net income, EPS, Free Cash Flow, and Adjusted EPS are expected to be at the lower-end of the guidance ranges for the full year 2023 provided on August 9, 2023 as a result of lower operating income being offset by lower net interest expense, lower taxes, and lower full year capital expenditures.

07:05 EST Ceva expands share repurchase program by 700,000 shares - Ceva announced that its board of directors authorized the expansion of the company's share repurchase program with an additional 700,000 shares of common stock available for repurchase. As of September 30, Ceva had approximately 144,000 shares of common stock available for repurchase under the existing plan, bringing the aggregate to approximately 844,000 shares available for repurchase.

06:42 EST Adient CEO Doug Del Grosso to retire, Jerome Dorlack to succeed - Adient announced that Doug Del Grosso has elected to retire as president, chief executive officer and a director of Adient's board of directors, effective December 31. Upon Del Grosso's retirement, Jerome Dorlack, currently Adient's executive vice president and chief financial officer, will be appointed president and CEO as well as a member of Adient's board. Mark Oswald, currently Adient's vice president, treasurer, investor relations and corporate communications, will be appointed executive vice president and CFO, succeeding Dorlack.

06:37 EST SeaWorld says 2024 revenue bookings trending up double-digit percentage - "Looking beyond the holiday season into 2024, we are pleased to see 2024 revenue bookings trending up double-digit percentage ahead of prior year for both 2024 groups and our Discovery Cove property. In addition, we recently launched our best pass benefits program ever which we expect will help drive increases in pass sales and a strong pass base for next year," continued Swanson.

06:17 EST Clear Secure announces $100M increase to stock repurchase program - In addition, the company announced that its board authorized a $100M increase to its existing Class A common stock share repurchase program, resulting in an aggregate remaining authorization of approximately $128M.

06:16 EST Clear Secure declares special cash dividend of 55c per share - Clear Secure announced that its board of directors declared a special cash dividend of 55c per share, payable on November 22 to holders of record of Class A Common Stock and Class B Common Stock as of the close of business on November 16.

06:15 EST Clear Secure increases quarterly dividend to 9c per share - Clear Secure announced that its board of directors declared a quarterly dividend of 9c per share, up from 7c last quarter payable on November 22 to holders of record of Class A Common Stock and Class B Common Stock as of the close of business on November 16.

05:40 EST Gan Limited to be acquired by Sega Sammy Creation for $1.97 per share in cash - Gan Limited announced that the company has entered into a definitive agreement and plan of merger with Sega Sammy Creation, or SSC, a wholly-owned subsidiary of Sega Sammy Holdings, an international conglomerate operating in the entertainment, gaming and resorts businesses. Under the merger agreement, at the effective time of the merger, each of Gan's issued ordinary shares will be converted into the right to receive in cash $1.97 per share, which reflects a premium of 121% over the closing price of Gan's ordinary shares on November 7, the last trading day prior to the date of this announcement. The proposed merger is subject to the approval of Gan shareholders. The company will ask its shareholders to consider and vote to approve the merger agreement at a special meeting of shareholders, which is expected to be held no later than March 31, 2024. Completion of the merger is not subject to a financing condition but is subject to the accuracy of the representations and warranties, performance of the covenants and other agreements included in the merger agreement, and customary closing conditions for a transaction of this type, including notification or approval with various gaming regulatory authorities. Assuming satisfaction of those conditions, the company expects the merger to close during the fourth quarter of 2024. If the merger is approved by Gan's shareholders and is completed, all outstanding Gan ordinary shares will be acquired for $1.97 per share in cash; Gan's ordinary shares will no longer be subject to public reporting requirements under the Securities Exchange Act of 1934; and its ordinary shares will no longer trade on any market. Upon completion of the merger, GAN will become a wholly owned subsidiary of SSC. The Gan board of directors formed a special committee, comprised solely of independent directors, to consider the transaction and to negotiate the price per shares and the terms of the merger agreement, with the assistance of financial and legal advisors. Based on the unanimous recommendation of the special committee, the Gan board of directors determined that the $1.97 price per share constitutes fair value for each company ordinary share, and determined that the terms of the agreement, the merger and the other agreements and transactions contemplated by the merger agreement are in the best interests of the company and its shareholders.

05:33 EST Gogoro announces riders can add scooter key to Apple Wallet - Gogoro (GGR) announced that its Smartscooter riders can now add a scooter key to Apple (AAPL) Wallet on their iPhone and Apple Watch. Smartscooter owners simply hold their device near the Smartscooter's NFC-enabled reader to unlock and start their vehicle. They will also be able to seamlessly share their scooter key with other iOS users. This capability is available to customers in Taiwan.

05:24 EST Addex Therapeutics regains compliance with Nasdaq - Addex Therapeutics announced it had received written notification from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550 and currently meets all other applicable criteria for continued listing.